TICAM1

Across TCGA pan-cancer cohorts, TICAM1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TICAM1 data layer compared with 21 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TICAM1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TICAM1 expression acts as an unfavorable survival marker.

OV and SARC are the cancer types where TICAM1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.285	0.843	<.001	36	view →
SARC	DFS	Median	All	0.081	0.632	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TICAM1–OV (OS)

Open the OV breakdown →